News & Media
Initiation of Canine Oral Cancer Study
Initiation of Canine Oral Cancer Study Trial & Enrollment Details Cary, NC and Roanoke,…
PRESS RELEASE: Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical | Company Launches Corporate Rebranding
RALEIGH, N.C. (November 1, 2022): Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held,…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial
This investment is in addition to the previously announced Series A investment of $5.5 million…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces $5.5M Series A Financing Round led by Khosla Ventures
The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Announces Issuance of US Patent for an Interventional Drug Delivery System
Raleigh, NC, June 30th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
PRESS RELEASE: Advanced Chemotherapy Technologies, Inc. Files IND Application for First in Human use of ACT-IOP-003 in Pancreatic Cancer Patients
Raleigh, NC, March 20th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
PRESS RELEASE: Notice of Allowance Received from U.S. Patent and Trademark Office for Patent Application with Claims Covering Combination Iontophoresis and Radiation Therapy
Raleigh, NC, August 30th, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
ACT announces receipt of Phase II NIH grant to support device development and first-in-human clinical trial for implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma
Raleigh, NC, August 22nd, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Leading the way toward greater hope for pancreatic cancer patients
Tony Voiers joined Advanced Chemotherapy Technologies as CEO after meeting with company co-founder Jen Jen…
NC companies shine at SEBIO Forum
November 18, 2018— Bioscience companies from North Carolina dominated the awards competition at the 20th…
Simulation Optimizes a Chemotherapy Implant to Treat Pancreatic Cancer
There are few illnesses as crafty as pancreatic cancer. It spreads like weeds and resists…
ACT announces receipt of NIH grant to support first in human clinical trial development and execution for an implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma.
Raleigh, NC, September 28th, 2018 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
‘In MedTech History’ – Oncology Device Technology
Fueled by the passion of pioneering physicists, physicians and medtech innovators looking for a way…
UNC Spinout Developing Device for Better Chemo Delivery
Pancreatic cancer is an elusive and deadly disease. It often has no initial symptoms, and…
Focal Medical, Inc.
111 James Jackson Ave. Suite 131
Cary, NC 27513
Focal Medical Copyright 2022 | Focal Medical is an equal opportunity employer
Terms of service – Privacy policy – Other policies